Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ: RETA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals's Return on Invested Capital Overview
Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q2 sales of $2.22 million. Earnings fell to a loss of $60.13 million, resulting in a 9.5% decrease from last... 
Via Benzinga
Why Reata Pharmaceuticals Stock Is Diving Today Despite Q2 Beats
The FDA pours cold water on the company's better-than-expected quarter. 
Via The Motley Fool
Topics Earnings
Exposures Financial Product Safety
Reata's Stock Plunges After FDA Identifies Review Issues With Bardoxolone Methyl US Application
Reata Pharmaceuticals Inc (NASDAQ: RETA) issued an update regarding its Bardoxolone Methyl application for chronic kidney disease (CKD) caused by Alport syndrome.... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also... 
Via Benzinga
Reata Pharmaceuticals, inc (RETA) Q2 2021 Earnings Call Transcript
RETA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
8 Stocks Moving In Monday's After-Hours Session
Gainers Kansas City Southern (NYSE: KSU) shares are trading higher following a report suggesting Canadian Pacific plans a new higher bid for the company, near $300 per share.... 
Via Benzinga
Reata Pharmaceuticals: Q2 Earnings Insights
Shares of Reata Pharmaceuticals (NASDAQ:RETA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 7.32%... 
Via Benzinga
Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals, Inc. to Report Second Quarter 2021 Financial Results and Provide an Update on Development Programs on August 9, 2021
From Reata Pharmaceuticals, Inc.
Via Business Wire
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2021
Upgrades Seaport Global upgraded the previous rating for Public Service Enterprise Group Inc (NYSE:PEG) from Neutral to Buy. Public Service Enterprise earned $1.28 in the... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
Unusual Options Activity Insight: Reata Pharmaceuticals
On Friday, shares of Reata Pharmaceuticals (NASDAQ:RETA) saw unusual options activity. After the option alert, the stock price moved up to $111.92. Sentiment: BULLISH Option... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers MoSys, Inc. (NASDAQ: MOSY) shares jumped 44.1% to settle at $5.46 on Wednesday. Lianluo Smart Limited (NASDAQ: LLIT) gained 24.6% to settle at $9.22. Reata... 
Via Benzinga
Why Reata Pharmaceuticals Stock Is Skyrocketing Today
The company might soon be taking a very big step toward FDA approval of an important pipeline drug. 
Via The Motley Fool
Exposures Product Safety
Mid-Afternoon Market Update: Dow Falls 1%; Iovance Biotherapeutics Shares Plunge
Toward the end of trading Wednesday, the Dow traded down 1.08% to 33,693.98 while the NASDAQ fell 0.66% to 13,215.41. The S&P also fell, dropping 0.94% to 4,088.99. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Lianluo Smart (NASDAQ:LLIT) stock rose 35.13% to $10.0 during Wednesday's regular session. Lianluo Smart's stock is trading at a volume of 4.6 million... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 5%; Reata Pharmaceuticals Shares Jump
Midway through trading Wednesday, the Dow traded down 1.32% to 33,610.27 while the NASDAQ fell 0.89% to 13,184.68. The S&P also fell, dropping 1.20% to 4,078.44. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Stocks Moving In Wednesday's Mid-Day Session
Gainers Advaxis, Inc. (NASDAQ: ADXS) shares jumped 43.1% to $0.6943 after jumping over 14% on Tuesday. MoSys, Inc. (NASDAQ: MOSY) shares gained 32% to $5.00. Reata... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates
Following the market opening Wednesday, the Dow traded down 1.47% to 33,559.29 while the NASDAQ fell 1.29% to 13,131.99. The S&P also fell, dropping 1.42% to 4,069.40. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Advaxis (NASDAQ:ADXS) shares increased by 27.34% to $0.62 during Wednesday's pre-market session. The company's market cap stands at $85.2 million. Lixte... 
Via Benzinga
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 24 stocks hit new 52-week lows. Noteworthy Mentions: The largest company in terms of market cap to set a new 52-week low was Canadian... 
Via Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.